YOUNGSTOWN, OH (CNN) - The Federal Drug Administration is anticipating a shortage of EpiPens, EpiPen Jr., and generic epinephrine auto-injectors.
The agency says manufacturing delays are the reason for what it expects to be a short-term shortage.
The products are still currently available.
The devices are made to deliver the lifesaving drug epinephrine during emergency treatment of serious allergic reactions, including anaphylaxis.
EpiPen producer Mylan NV confirms what it calls (quote) "intermittent supply constraints."
Mylan asks patients having problems getting EpiPens to contact its customer relations phone number (800) 796-9526 for help finding pharmacies that have them in stock.
- FDA anticipates EpiPen shortage
- FDA extends some EpiPen expiration dates due to shortage
- US approves new generic competitor to EpiPen
- Drugmaker to sell cheaper generic rival to EpiPen injectors
- FDA warns of common blood pressure medicine shortage due to recalls
- FDA approves preventive migraine treatment
- FDA expands e-cigarette investigation
- FDA approves powerful new opioid
- FDA proposes new sunscreen regulations
- FDA approves first postpartum depression drug